Figure 5
From: Efficacy of auranofin as an inhibitor of desmoid progression
Schedule of auranofin administration for Apc1638N mice and effects of auranofin in in vivo DF development model mice. (A) Representative findings of tumor development in a Apc1638N mouse (6 months of age) (black arrows: tumorous tissues). Small white tumorous tissues of a few millimeters in size occurred subcutaneously and on the fascia. (B) The number of tumors that developed in Apc1638N (6 months of age) with or without treatment of auranofin by oral or intraperitoneal administration. Oral dose for mice was set at 1.0 mg/kg/day and the intraperitoneal dose was set as 1 mg/kg three times a week. The average number of tumors developed with oral administration of auranofin (10 male mice and 13 female mice) and control (7 male mice and 8 female mice), ant that with intraperitoneal administration of auranofin (8 male mice and 9 female mice) and control (8 male mice and 12 female mice) were plotted. *P < 0.01. (C) Pathological findings of the tumors developed in mice with or without treatment of auranofin by oral administration (6 months of age) (H&E, × 200). p.o.: per OS. (D) Experimental procedure in vivo. Auranofin was administered from 5 weeks to 6 months of age. Two separate experiments were performed based on the administration route, oral and intraperitoneal. Mice were sacrificed at 6 months of age, and the number of tumors, tumor size, tumor weight were calculated. Tumorous tissues were also subjected to histological examination.
